Pipeline
Debiopharm’s projects cover all molecule type proteins, peptides, small molecules
Oncology
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ xevinapant (Debio 1143)
Head & Neck Cancer – IAP antagonist
IAP antagonist
Merck
_ with avelumab
NSCLC – IAP antagonist
IAP antagonist
Merck
_ with nivolumab
Selected solid tumors nivolumab – IAP antagonist
IAP antagonist
Merck
_ with pembrolizumab
Selected solid tumors pembrolizumab – IAP antagonist
IAP antagonist
Merck
_ naratuximab emtansine (Debio 1562)
Diffuse large B-cell lymphoma – Anti-CD37 ADC
Anti-CD37 ADC
ODD
_ Debio 1124
Medullary thyroid cancer – Minigastrin-Lu177
Minigastrin-Lu177
_ Debio 1124
Small cell lung cancer – Minigastrin-Lu177
Minigastrin-Lu177
_ Debio 4228
Oncology – Undisclosed
Undisclosed
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
Merck
ODD: Orphan Drug Designation
Merck: Merck
Infectious disease
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ afabicin (Debio 1450)
Bone & joint infections – FabI inhibitor
FabI inhibitor
ODD/FT/QIDP
_ afabicin (Debio 1450)
ABSSSI – FabI inhibitor
FabI inhibitor
FT/QIDP
_ Debio 1561
Infectious diseases – Sample prep. Technology
Sample prep. Technology
_ alisporivir (Debio 025)
SARS-CoV-2 – Cyclophilin inhibitor
Cyclophilin inhibitor
_ alisporivir (Debio 025)
GI disorders – Cyclophilin inhibitor
Cyclophilin inhibitor
_ Debio 1453
N. gonorrhoeae – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/S
A. baumannii – Fabl inhibitor
Fabl inhibitor
CARB-X
_ Debio 1454/M
GI disorders – microbiome remodeling
microbiome remodeling
Takeda
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X
Takeda: Takeda
Our commercialized products
Clinical trials
Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.